Home » GUIDANT EXECS IN HOT SEAT FOR UNTIMELY STOCK SALES
GUIDANT EXECS IN HOT SEAT FOR UNTIMELY STOCK SALES
In the wake of Guidant's breakup with Johnson & Johnson, insiders who sold
or disposed of more than $130 million in stock since Dec. 15 are being dogged
by the old Watergate question: What did they know and when did they know it?
It has gotten the attention of the Securities and Exchange Commission, which
is investigating the company's product disclosures and individual stock trading.
It's also the thrust of several shareholder lawsuits filed since July 1, and
it's at the heart of New York Attorney General Eliot Spitzer's complaint lodged
last week as the deal unraveled.
The
Indianapolis Star
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May